ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Wezenla 130 mg/26 ml, Konzentrat zur Herstellung einer Infusionslösung - 
70187001 Amgen Switzerland AG
Wezenla 130 mg/26 ml, Konzentrat zur Herstellung einer Infusionslösung23.07.2025
  23.07.2025
Ustekinumab (L04AC05) 
WHO-DDD22.07.2030
 
07.15. 
B  
No 
  
PR  
k.A.PR
  
7680701870015Biotechnologika
  
Composition
ustekinumabum 130 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, dinatrii edetas, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 26 ml, natrium 0.097 mg.
Packungsbestandteile
Concentrate for infusion
 
 
Active AgentDose
 130mg / 26ml
 
Inactive agents
 
Histidin Hydrochloride Monohydrate
Histidine
Methionine
Sodium Hydroxide
Polysorbatum 80
Saccharum
Source
Data was imported : 07.08.2025 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home